Marea Therapeutics, Inc., a clinical-stage biotechnology company, has announced its upcoming participation in the 93rd European Atherosclerosis Society (EAS) Congress, set to take place from May 4-7, 2025, in Glasgow, UK. The company will present two key studies, showcasing its cutting-edge research and advancements in cardioendocrine diseases, a field where they are pioneering innovative treatment approaches.
Founded with a focus on transforming the treatment of cardioendocrine diseases, Marea Therapeutics harnesses human genetics to design next-generation medicines. The company’s research aims to address unmet medical needs, particularly in metabolic dysfunction and cardiovascular diseases. Marea’s pipeline includes promising treatments targeting both cardiovascular and endocrine diseases, with its lead program, MAR001, currently in Phase 2 clinical development.
MAR001 is being evaluated for its efficacy in treating adults with metabolic dysfunction who are at high risk for cardiovascular disease. The company is also advancing MAR002, which is targeted at acromegaly, a rare disease caused by excess growth hormone. Marea’s research leverages cutting-edge gene therapy and molecular techniques to create treatments that aim to be more effective, safe, and sustainable than current therapies.
Marea Therapeutics will deliver two oral presentations at the EAS Congress, shedding light on its novel therapies and the role of remnant cholesterol in cardiovascular disease.
A Novel ANGPTL4 Inhibitory Antibody Safely Lowers Plasma Triglycerides and Remnant Cholesterol in Humans
This late-breaking session, scheduled for Wednesday, May 7, 2025, from 11:00 a.m. – 12:30 p.m. BST, will present data on Marea’s ANGPTL4 inhibitory antibody, a novel approach for managing plasma triglycerides and remnant cholesterol. The data demonstrates the safety and efficacy of this antibody in humans, providing a new avenue for managing dyslipidemia, a key risk factor for cardiovascular disease. ANGPTL4 has shown promise in reducing triglyceride levels, which are often linked to cardiovascular events, making this presentation significant for the treatment of high-risk cardiovascular patients.
Real-world Analysis of the Association of Remnant Cholesterol Levels with Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease
On Tuesday, May 6, 2025, from 2:35 p.m. – 3:35 p.m. BST, Marea will present a real-world analysis highlighting the relationship between remnant cholesterol levels and major cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD). This session will explore how elevated remnant cholesterol levels correlate with increased cardiovascular risk, emphasizing the importance of managing lipid levels to prevent cardiovascular events.
Marea’s Commitment to Innovation
Marea Therapeutics is deeply committed to advancing the science behind cardioendocrine diseases. The company’s innovative approach leverages human genetics to create first-in-class therapies, which are designed to not only improve patient outcomes but also significantly reduce healthcare costs over time. Marea’s work could reshape the landscape of cardiovascular and endocrine disease treatment, offering hope to millions of patients worldwide.
The company’s participation in the EAS Congress underscores its leadership in cardiovascular research and commitment to advancing clinical science.
